Aurobindo Pharma Quarterly Results for Trading Insights
In Sept 2025, Aurobindo Pharma (AUROPHARMA) reported revenue ₹8,359 Cr and net profit ₹848 Cr — revenue +7.4% YoY. For annual financials, live price and key ratios, visit Aurobindo Pharma share price chart.
AUROPHARMA Quarterly Results — Revenue, Profit & EPS Highlights
Aurobindo Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with AUROPHARMA fair price to assess whether the stock is under or overvalued.
- Revenue of ₹8,359 Cr in Sept 2025 (-1.8% vs Mar 2025, +7.4% vs Sept 2024)
- Net Profit of ₹848 Cr in Sept 2025 (-6.1% vs Mar 2025, +3.8% vs Sept 2024)
- EBITDA of ₹1,752 Cr in Sept 2025 (-7.5% vs Mar 2025)
- Operating Margin of 20.0% in Sept 2025 (-1.0pp vs Mar 2025)
- Earnings Per Share of ₹14.61 in Sept 2025 (-6.1% vs Mar 2025)
Aurobindo Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS
AUROPHARMA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 8,359 | 8,516 | 7,899 | 8,793 | 7,783 | -1.8% | 7.4% |
| Net Profit (₹ Cr) | 848 | 903 | 824 | 910 | 817 | - | - |
| EBITDA (₹ Cr) | 1,752 | 1,894 | 1,634 | 1,855 | 1,553 | - | - |
| EPS (₹) | 14.61 | 15.56 | 14.20 | 15.67 | 14.00 | - | - |
| Operating Margin (%) | 20.0% | 21.0% | 20.0% | 19.0% | 19.0% | - | - |
AUROPHARMA Share Price Trend — 1-Year Movement Across Quarterly Results
Aurobindo Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore AUROPHARMA stock price history to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
AUROPHARMA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Aurobindo Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹415,924.72 Cr | 1808.3 | 14,875 | 3,125 | +10.8% | - | 21.0% | 139.1 |
|
Divis Laboratories
Sept 2025 |
₹171,625.44 Cr | 6502.5 | 2,860 | 689 | +7.1% | - | 24.1% | 250.4 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹142,059.09 Cr | 4185.1 | 3,219 | 591 | +11.3% | - | 18.4% | 238.6 |
|
Dr Reddys Laborator…
Sept 2025 |
₹110,348.15 Cr | 1322.9 | 9,135 | 1,337 | +1.1% | - | 14.6% | 81.8 |
|
Cipla
Sept 2025 |
₹105,996.98 Cr | 1309.6 | 7,716 | 1,353 | +12.0% | - | 17.5% | 78.3 |
All amounts in ₹ Crores